A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Summary
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Arms & interventions
- Drugmezigdomide
Specified dose on specified days
- DrugPomalidomide
Specified dose on specified days
- DrugBortezomib
Specified dose on specified days
- DrugDexamethasone
Specified dose on specified days
Outcome measures
Primary
Progression-free Survival (PFS)
Time frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)
Secondary
Recommended mezigdomide dose
Time frame: Up to 12 Months
Plasma concentrations of mezigdomide
Time frame: Up to 134 Days
Overall Survival (OS)
Time frame: From date of randomization to date of death due to any cause (Up to approximately 5 years)
Overall Response (OR)
Time frame: Up to approximately 5 years
Complete Response (CR) or better
Time frame: Up to approximately 5 Years
Very Good Partial Response (VGPR) or better
Time frame: Up to approximately 5 years
Time to Response (TTR)
Time frame: Up to approximately 5 years
Duration of Response (DOR)
Time frame: Up to approximately 5 years
Time to Progression (TTP)
Time frame: Up to approximately 5 years
Time to Next Treatment (TTNT)
Time frame: Up to approximately 5 years
Progression-free Survival 2 (PFS-2)
Time frame: Up to approximately 5 years
Minimal Residual Disease (MRD) negativity
Time frame: Up to approximately 5 years
Number of participants with Adverse Events (AEs)
Time frame: Up to approximately 5 years
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores
Time frame: Up to approximately 5 years
Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score
Time frame: Up to approximately 5 years
Eligibility criteria
Study locations (56)
Local Institution - 0366
Los Alamitos, California, 90720
Local Institution - 0272
San Diego, California, 92123
Local Institution - 0273
West Hollywood, California, 90069
Local Institution - 0381
Aurora, Colorado, 80045
Local Institution - 0380
Farmington, Connecticut, 06030
Local Institution - 0208
New Haven, Connecticut, 06510
Local Institution - 0303
Coral Springs, Florida, 33321
Local Institution - 0403
Fort Myers, Florida, 33901
Local Institution - 0401
St. Petersburg, Florida, 33701
Local Institution - 0402
West Palm Beach, Florida, 33401
Local Institution - 0211
Athens, Georgia, 30607
Local Institution - 0048
Marietta, Georgia, 30060
Local Institution - 0330
Garden City, Kansas, 67846
Local Institution - 0080
Westwood, Kansas, 66205
Local Institution - 0358
Baton Rouge, Louisiana, 70808
Local Institution - 0255
New Orleans, Louisiana, 70112
Local Institution - 0385
Shreveport, Louisiana, 71103
Local Institution - 0357
Baltimore, Maryland, 21215
Local Institution - 0246
Boston, Massachusetts, 02215
Local Institution - 0271
Ann Arbor, Michigan, 48109
Local Institution - 0364
Detroit, Michigan, 48202
Local Institution - 0410
Minneapolis, Minnesota, 55404
Local Institution - 0088
Hattiesburg, Mississippi, 39401
Local Institution - 0242
Jackson, Mississippi, 39213
Local Institution - 0288
East Brunswick, New Jersey, 08816
Local Institution - 0363
Ridgewood, New Jersey, 07450
Local Institution - 0302
Albuquerque, New Mexico, 87131
Local Institution - 0245
Buffalo, New York, 14215
Local Institution - 0257
Lake Success, New York, 11042
Local Institution - 0373
New Hyde Park, New York, 11042
Local Institution - 0371
New York, New York, 10028
Local Institution - 0108
Rochester, New York, 14621
Local Institution - 0374
Shirley, New York, 11967
Local Institution - 0372
The Bronx, New York, 10469
Local Institution - 0274
Williamsville, New York, 14221
Local Institution - 0260
Durham, North Carolina, 27710
Local Institution - 0400
Cincinnati, Ohio, 45242
Local Institution - 0377
Cleveland, Ohio, 44111
Local Institution - 0076
Cleveland, Ohio, 44195
Local Institution - 0376
Mayfield Heights, Ohio, 44124
Local Institution - 0359
Allentown, Pennsylvania, 18103
Local Institution - 0264
York, Pennsylvania, 17403
Local Institution - 0223
Germantown, Tennessee, 38138
Local Institution - 0378
Abilene, Texas, 79606
Local Institution - 0275
Houston, Texas, 77030
Local Institution - 0267
San Antonio, Texas, 78229
Local Institution - 0409
San Antonio, Texas, 78240
Local Institution - 0207
Salt Lake City, Utah, 84106
Local Institution - 0297
Fredericksburg, Virginia, 22408
Local Institution - 0408
Norfolk, Virginia, 23502
Local Institution - 0399
Roanoke, Virginia, 24014
Local Institution - 0268
Seattle, Washington, 98108
Local Institution - 0293
Seattle, Washington, 98109
Local Institution - 0097
Spokane, Washington, 99208
Local Institution - 0411
Vancouver, Washington, 98684
Local Institution - 0220
Madison, Wisconsin, 53792